Heath Lukatch - Jan 29, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Director
Signature
Heath Lukatch, by /s/ Andrew Guggenhim, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Jan 29, 2024
Transactions value $
-$206,000
Form type
4
Date filed
1/31/2024, 04:12 PM
Previous filing
Jan 4, 2024
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $64K +4K +71.11% $16.00 9.63K Jan 29, 2024 Direct
transaction PCVX Common Stock Sale -$270K -4K -41.56% $67.50 5.63K Jan 29, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -4K -26.67% $0.00 11K Jan 29, 2024 Common Stock 4K $16.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023.
F2 Fully vested and exercisable.